Clinical trials: Allergy to House Dust Mites
House Dust Mite Allergy, House Dust Mite Rhinitis
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
Rationale: Allergic rhinitis/rhinoconjunctivitis (ARC) is a global health problem, affecting 10-25% of the population. Allergen-specific immunotherapy is the only disease-modifying therapeutic option for subjects with house dust…
- Trial name
- NCT06920771
- Testing
- PURETHAL Mites 50,000 AUeq/ml
- Where
- 68 sites in Bulgaria, Germany and 3 more
- Volunteers
- 691 people
- Sponsor
- HAL Allergy
Dermatitis, Atopic
Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)
The Early Prevention of Asthma in Atopic Children (EPAAC™). 24 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in 12 to 24 months old children.
- Trial name
- NCT00152464
- Testing
- Levocetirizine
- Volunteers
- 514 people
- Sponsor
- UCB Pharma SA
Perennial Allergic Rhinoconjunctivitis, House Dust Mite Allergy
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
The purpose of the study is to test the efficacy of the combination treatment AllQbG10 in patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy in a double-blind placebo-controlled setting
- Trial name
- NCT00574223
- Testing
- CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Cytos Biotechnology AG
Allergy to House Dust Mite, Allergic Asthma
Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients
The study will be conducted as a randomized, double-blind, placebo-controlled, single-center study in adult patients with mild controlled allergic asthma and house dust mite allergy.
- Trial name
- Tregulaire (NCT04673591)
- Testing
- Tregalizumab
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- T-Balance Therapeutics GmbH
House Dust Mite Allergy, Birch Pollen Allergy
Evaluation of an Adjusted Cutoff Value for S.P.A.T (Skin Prick Automated Test) Device in Allergic Subjects
Skin prick test (SPT) is a first line diagnostic test to detect type I hypersensitivity in patients suspected of an inhalant allergy. A novel S.P.A.T.
- Trial name
- SPATprovocatio (NCT06803953)
- Testing
- Skin Prick Automated Test, Skin Prick Manual Test, Nasal Allergen Challenge
- Where
- France
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Hippocreates
Allergic Asthma, Allergy to House Dust
Validation of Strasbourg Environmental Exposure Chamber ALYATEC in Mite Allergic Subjects With Asthma
This is a randomized, double blind, cross-over study designed to determine the concentration of airborne house dust mite allergen inducing bronchial response in asthmatic subjects allergic to mite, during allergen exposures in…
- Conditions
- Allergic Asthma, Allergy to House Dust, Allergy
- Trial name
- NCT04663880
- Testing
- Exposure to three concentrations of HDM allergen in EEC, Exposure to a single concentration of HDM allergen in EEC
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Alyatec
Venous Thromboembolism, Atopic Dermatitis
The Incidence of Venous Thromboembolism in Atopic Dermatitis
This study aims to investigate the incidence of venous thromboembolism in people who are diagnosed with atopic dermatitis.
- Conditions
- Venous Thromboembolism, Atopic Dermatitis, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- NCT04969653
- Testing
- Exposure of venous thromboembolism
- Where
- United Kingdom
- Volunteers
- 754,745 people
- Sponsor
- Momentum Data
Perennial Allergic Rhinitis
The Effect of Nasal Carbon Dioxide (CO2) on Nasal Congestion in Subjects With Perennial Allergic Rhinitis
The purpose of this study is to evaluate the effect of nasal CO2 on nasal congestion and other symptoms related to Perennial Allergic Rhinitis.
- Trial name
- NCT00638755
- Testing
- Nasal Carbon Dioxide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Capnia, Inc.
House Dust Mite Allergy, Rhinoconjunctivitis
ToleroMune House Dust Mite Follow on Study
House Dust Mites (HDM) are arachnids that infest bedding, carpet, upholstered furniture and fabric. Like many other allergens, exposure to HDM allergens in sensitised patients is associated with poorer lung function, greater…
- Trial name
- NCT01923792
- Volunteers
- 105 people
- Sponsor
- Circassia Limited
Allergic Rhinitis, Allergic Rhinoconjunctivitis
MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)
The purpose of this study is to assess the effect on various biomarkers of treatment with MK-8237 in participants with allergic rhinitis or rhinoconjunctivitis.
- Trial name
- NCT01852825
- Testing
- MK-8237, NAC
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)
The purpose of this study is to evaluate the dose-related effectiveness, the safety and the tolerability of MK-8237, compared to placebo, in the treatment of house dust mite (HDM)-induced allergic rhinitis/rhinoconjunctivitis in…
- Trial name
- NCT01644617
- Testing
- MK-8237 6 DU, MK-8237 12 DU
- Volunteers
- 124 people
- Sponsor
- ALK-Abelló A/S
Allergy
Safety of ToleroMune House Dust Mite (HDM) to Treat House Dust Mite Allergy in HDM Allergic Subjects With Rhinoconjunctivitis
The prevalence of allergic sensitisation to House Dust Mite (HDM) varies from region to region and depends on the regional prevalence of HDM.
- Trial name
- NCT01008332
- Testing
- Toleromune HDM
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Circassia Limited
House Dust Mite Allergy, Perennial Allergic Rhinitis
Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis
Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate…
- Conditions
- House Dust Mite Allergy, Perennial Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma
- Trial name
- NCT05400811
- Testing
- MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL)
- Where
- 16 sites in Spain
- Volunteers
- 400 people
- Sponsor
- Inmunotek S.L.
House Dust Mite Allergy
Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis
The trial is performed to assess efficacy and safety of Novo-Helisen Depot in allergic Rhinoconjunctivitis
- Trial name
- NCT00263549
- Testing
- House dust mite Novo Helisen Depot
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
Rhinitis, Allergic, Perennial
Probiotic Administration and Perennial Allergic Rhinitis
The purpose of this study is to evaluate the efficacy of a probiotic strain in improving the quality of life in adult subjects suffering from perennial allergic rhinit.
- Trial name
- NCT01779895
- Testing
- Lactobacillus paracasei probiotic strain
- Where
- Switzerland
- Volunteers
- 64 people
- Sponsor
- Société des Produits Nestlé (SPN)
Mite Allergy, Dermatophagoides Farinae Allergy
Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte
House dust mites are the main source of allergies in indoor environments. They are predominant in coastal areas, with the Canary Islands being the autonomous community with the highest percentage of patients with…
- Conditions
- Mite Allergy, Dermatophagoides Farinae Allergy, Dermatophagoides Pteronyssinus Allergy, Rhinitis, Allergic
- Trial name
- NCT07427576
- Testing
- Clustoid® Max Forte
- Where
- 2 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Inmunotek S.L.
Allergic Rhinitis, Allergic Asthma
Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract
Prospective, randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of polymerized and mannan conjugated allergen extract of Dermatophagoides for the treatment of allergic…
- Conditions
- Allergic Rhinitis, Allergic Asthma, Allergic Rhinoconjunctivitis, Allergy to House Dust Mite
- Trial name
- MM09-SLIM (NCT05641272)
- Testing
- 3,000 MM09, 9,000 MM09
- Where
- Argentina
- Volunteers
- 90 people
- Sponsor
- Inmunotek S.L.
Asthma, House Dust Mite Allergy
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts
The purpose of this study is to investigate the safety of different doses of sublingual tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma.
- Trial name
- NCT01608243
- Testing
- SLIT tablets of house dust mite allergen extracts
- Where
- France
- Volunteers
- 94 people
- Sponsor
- Stallergenes Greer
Allergy Dermatophagoides Pteronyssinus, Allergic Rhinitis
Biological Standardization of Dermatophagoides Pteronyssinus Allergen Extract
The objective of this study is to determine the biologic activity of a Dermatophagoides pteronyssinus allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Conditions
- Allergy Dermatophagoides Pteronyssinus, Allergic Rhinitis, Allergic Asthma
- Trial name
- NCT01821716
- Testing
- Prick test Dermatophagoides pteronyssinus allergen extract
- Where
- 2 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Laboratorios Leti, S.L.